clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Serositis D012700 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Achlorhydria D000126 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Eye Infections D015817 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Ammon S et al. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. 2000 Aliment. Pharmacol. Ther. pmid:10848660
Sharara AI et al. Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. 2015 Aliment. Pharmacol. Ther. pmid:26238584
Datta S et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. 2005 Aliment. Pharmacol. Ther. pmid:15963080
Gisbert JP and Calvet X Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. 2012 Aliment. Pharmacol. Ther. pmid:22129228
Lehmann FS et al. Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. 2000 Aliment. Pharmacol. Ther. pmid:10735923
Miwa H et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. 2000 Aliment. Pharmacol. Ther. pmid:10735925
Malfertheiner P et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. 2003 Aliment. Pharmacol. Ther. pmid:12969088
Hassan C et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. 2003 Aliment. Pharmacol. Ther. pmid:12969091
Malfertheiner P et al. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. 2002 Aliment. Pharmacol. Ther. pmid:11860399
Miwa H et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. 1999 Aliment. Pharmacol. Ther. pmid:10383502
Ducóns JA et al. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. 1999 Aliment. Pharmacol. Ther. pmid:10383507
Vakil N et al. Seven-day therapy for Helicobacter pylori in the United States. 2004 Aliment. Pharmacol. Ther. pmid:15225176
Dobrilla G et al. Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9692703
Savarino V et al. A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. 1997 Aliment. Pharmacol. Ther. pmid:9305478
Broutet N et al. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. 2003 Aliment. Pharmacol. Ther. pmid:12492738
Ott EA et al. Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. 2005 Aliment. Pharmacol. Ther. pmid:15882244
Chen PY et al. Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28074519
Zamani M et al. Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. 2017 Aliment. Pharmacol. Ther. pmid:28074507
Laine L and Dhir V Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. 2002 Aliment. Pharmacol. Ther. pmid:12030957
Vallve M et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. 2002 Aliment. Pharmacol. Ther. pmid:12030958